Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Adrianus de Langen

Has grant

The Netherlands Cancer Institute

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Recent Grants

Grant: Close

PET imaging

Open Date:

Close Date:

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Collaborators (20)

Adrian Sacher

Associate Professor

University of Toronto

CANADA

View details

Sanjay Popat

Reader

Institute of Cancer Research

UNITED KINGDOM

View details

Koen Hartemink

Prof. dr.

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

Bjørn Henning Grønberg

Professor

Norwegian University of Science and Technology

NORWAY

View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES

View details

Mathilde Kouwenhoven

Neurologist

VU medisch centrum

NETHERLANDS

View details

Bart A Westerman

Associate Professor

VU medisch centrum

NETHERLANDS

View details

Anthonie van der Wekken

Scientific Staff

University of Groningen

NETHERLANDS

View details

Victor Thijssen

Associate Professor / Principal Investigator

Amsterdam University Medical Centers

NETHERLANDS

View details

Kim Monkhorst

The Netherlands Cancer Institute

NETHERLANDS

View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Darren Wan-Teck Lim

Assoc Prof

SINGAPORE

View details

Kenneth O'Byrne

Queensland University of Technology

AUSTRALIA

View details

Dong-Wan Kim

Associate Professor

Seoul National University Hospital

SOUTH KOREA

View details

Javier De Castro

Scientific Director

La Paz University Hospital

SPAIN

View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA

View details

Helena A. Yu

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Egbert Smit

Leiden University Medical Center

NETHERLANDS

View details

Alessandra Curioni-Fontecedro

Professor of Oncology

University of Fribourg

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adrianus de Langen

Research Interests

Explore related searches

Recent Grants

Articles (10)

Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.

Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET‐Guided Verification

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Collaborators (20)

Adrian Sacher

Sanjay Popat

Koen Hartemink

Bjørn Henning Grønberg

Jonathan W. Goldman

Mathilde Kouwenhoven

Bart A Westerman

Anthonie van der Wekken

Victor Thijssen

Kim Monkhorst

David S. Hong

Darren Wan-Teck Lim

Kenneth O'Byrne

Dong-Wan Kim

Javier De Castro

Ferdinandos Skoulidis

Benjamin Solomon

Helena A. Yu

Egbert Smit

Alessandra Curioni-Fontecedro

Make your next move.

Adrianus de Langen

Research Interests

Explore related searches

Recent Grants

Articles (10)

Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Molecular determinants of sotorasib clinical efficacy in KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated non-small-cell lung cancer.

Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET‐Guided Verification

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Collaborators (20)

Adrian Sacher

Sanjay Popat

Koen Hartemink

Bjørn Henning Grønberg

Jonathan W. Goldman

Mathilde Kouwenhoven

Bart A Westerman

Anthonie van der Wekken

Victor Thijssen

Kim Monkhorst

David S. Hong

Darren Wan-Teck Lim

Kenneth O'Byrne

Dong-Wan Kim

Javier De Castro

Ferdinandos Skoulidis

Benjamin Solomon

Helena A. Yu

Egbert Smit

Alessandra Curioni-Fontecedro

Make your next move.

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.